RNF and Betaseron® Tolerability Study

• Status: Completed
• Trial end date: 2009-09-01

Summary

To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.

• Phase: Phase 3

Details

• Lead Sponsor: EMD Serono
• Collaborator: Pfizer
• Treatments: Interferon beta-1a; Interferon beta-1b; Interferon-beta; Interferons